Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple...

Area of Science:

• Hematology
• Oncology
• Clinical Epidemiology

Background:

• The International Prognostic Index (IPI) is widely used for diffuse large B-cell lymphoma (DLBCL) prognostication.
• Several IPI variations, including revised IPI (R-IPI) and National Comprehensive Cancer Network IPI (NCCN-IPI), have been proposed but require validation.

Purpose of the Study:

• To validate and compare the predictive accuracy of various IPI-like models for survival in newly diagnosed DLBCL patients.
• To identify the most accurate prognostic model for DLBCL.

Main Methods:

• Retrospective analysis of 5126 DLBCL patients treated with immunochemotherapy.
• Comparison of 13 different prognostic models, including IPI and its variations.
• Evaluation of model performance based on prediction accuracy, discrimination, and calibration.

Main Results:

• All evaluated models demonstrated some ability to predict survival.
• The NCCN-IPI consistently exhibited high predictive accuracy.
• Five-year overall survival in the NCCN-IPI high-risk group was 33.4%, consistent with prior validation.
• Models with fewer risk groups or lacking age as a factor showed poorer performance.

Conclusions:

• The NCCN-IPI is a highly accurate prognostic model for newly diagnosed DLBCL patients.
• NCCN-IPI should be reported as a reference model alongside the traditional IPI for DLBCL.
• Further validation of novel prognostic models for DLBCL is warranted.